[Federal Register Volume 65, Number 114 (Tuesday, June 13, 2000)]
[Notices]
[Pages 37142-37146]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-14829]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 00097]


Uniform Population-Based Approach to Case Ascertainment, 
Typology, Surveillance, and Research on Childhood Diabetes; Notice of 
Availability of Funds

A. Purpose

    The Centers for Disease Control and Prevention (CDC) announces the 
availability of fiscal year (FY) 2000 funds for a cooperative agreement 
program to develop a multi-center and uniform population-based approach 
to case ascertainment, typology, surveillance, and research on 
childhood diabetes (diagnosis before the age of 20 years). This program 
addresses the ``Healthy People 2010'' focus area of Diabetes. For the 
conference copy of ``Healthy People 2010,'' visit the internet site: 
http://www.healthypeople>. In view of the importance of racial and 
ethnic health disparity issues, the purpose of the program is to use a 
uniform multi-center approach in diverse populations for multiple 
purposes:
    1. Using existing data of known prevalent cases of childhood 
diabetes, develop a uniform typology of the prevalent cases, obtain 
type-specific prevalence estimates, and describe characteristics of the 
different types of childhood diabetes;
    2. Based on the extensive collection of new cases of childhood 
diabetes, develop a uniform typology of the incident cases, obtain 
accurate and precise population-based estimates of the type-specific 
incidence and secular trends of new cases, and describe the 
characteristics of the different types of childhood diabetes;
    3. Develop a uniform approach to follow incident cases of childhood 
diabetes to ascertain changes in typology, characteristics and 
outcomes, and to maintain a ``pool'' of incident cases of childhood 
diabetes.
    Characterization of types of childhood diabetes should include a 
description of potential risk factors (including family history, 
maternal diabetes, race/ethnicity, sex, weight and height, birth-
weight, etc), other characteristics (including presence of acanthosis 
nigricans, symptoms and circumstances at or preceding diagnosis, 
treatment and response to treatment, HbA1c, lipids, and blood pressure 
levels, etc), potential laboratory measurements (C-peptide and insulin 
levels, immunological markers, etc), potential complications (including 
microalbuminuria, hypertension, retinopathy, neuropathy, infections, 
etc), and quality of medical care (including screening frequencies for 
HbA1c, lipid profiles, microalbuminuria, retinal and foot examinations, 
blood pressure checks, nutrition counseling, rates of hospitalization 
for complications, etc).
    This collaborative program will consist of two phases. Phase I (12 
months)--Planning, developing networks of care providers and other 
partnerships, and collaboration on the development of the protocol and 
Institutional Review Board clearances. Phase II (48 months)--Data 
collection, monitoring, analyzes, and collaborative reporting of the 
results, on a yearly basis.

B. Eligible Applicants

    Applications may be submitted by public and private nonprofit 
organizations and by governments and their agencies; that is, 
universities, colleges, research institutions, hospitals, other public 
and private nonprofit organizations, State and local governments or 
their bona fide agents, and federally recognized Indian tribal 
governments, Indian tribes, or Indian tribal organizations.

    Note: Public Law 104-65 states that an organization described in 
section 501(c)(4) of the Internal Revenue Code of 1986 that engages 
in lobbying activities is not eligible to receive Federal funds 
constituting an award, grant, cooperative agreement, contract, loan, 
or any other form.

C. Availability of Funds

    Approximately $500,000 is available in FY 2000 to fund 
approximately 2 to 3 awards. It is expected that the average award will 
be $200,000 ranging from $150,000 to $250,000. It is anticipated that 
additional funds may be available in FY 2001-2004 to increase the 
average award to approximately $500,000 in Years 2-5, ranging from 
$400,000 to $600,000. It is expected that the awards will begin on or 
about September 30, 2000, and will be made for a 12-month budget period 
within a project period of up to 5 years.

[[Page 37143]]

Funding Estimates May Change

    Continuation awards within an approved project period will be made 
on the basis of satisfactory progress as evidenced by required reports 
and the availability of funds.

Use of Funds

    Funds are awarded for a specifically defined purpose and must be 
targeted for implementation and management of the project. Funds can 
support personnel, activities directly related to the project, and the 
purchase of software for data collection, analysis, and project 
management and evaluation purposes.
    Prohibited Uses: Cooperative agreement funds under this program 
announcement cannot be used for (1) construction, (2) renovation, (3) 
the purchase or lease of passenger vehicles or vans, (4) to supplant 
non-federal funds that would otherwise be made available for this 
purpose, or (5) cost of regular patient care.

Funding Priority

    In making awards, priority consideration will be given as follows. 
Due to the high prevalence of type 2 diabetes in American Indian 
children, funding priority will be given to at least one center which 
will have access to American Indian populations. In addition, approved 
applications may also be ranked and funded based on populations with 
racial/ethnic and socio-economic diversity to achieve geographic, 
socio-economic and racial/ethnic representation of the U.S. population, 
and a minimum mix of the different types of childhood diabetes (at 
least 20% type 2).

Minimum Requirement

    Applications for the development of a multi-center and uniform 
population-based approach to case ascertainment, typology, 
surveillance, and research on childhood diabetes in diverse populations 
require access to information on large numbers of children with 
diabetes (minimum of 50 incident cases per year) and their referent 
populations (minimum of 300,000 children under the age of 20) with 
racial/ethnic and socio-economic diversity, including under-insured.
    Institutions may apply as a single entity or in collaborative 
partnership or network(s). However, only one institution will be named 
as the recipient of funds in a partnership/network.
    Eligibility characteristics for review must be clearly specified 
with appropriate documentation in the Application Requirements section 
of your application (see Application Content).

D. Program Requirements

    In conducting activities to achieve the purpose of this program, 
the recipient will be responsible for the activities under 1. 
(Recipient Activities), and CDC will be responsible for the activities 
listed under 2. (CDC Activities).

1. Recipient Activities

    a. Establish and sustain networks or partnerships with health care 
providers and health care systems who have access to information on 
cases of childhood diabetes. Collaborate with other health 
organizations, community groups, State Health Department, Diabetes 
Control Programs etc., as necessary to accomplish program activities.
    b. Establish a Steering Committee that will be the primary 
governing body of the study and will be comprised of each of the 
Principal Investigators from each center. The Steering Committee will 
have primary responsibility for developing manual(s) of operations and 
common study protocols, submitting the protocols for CDC and other 
Institutional Review Boards, and coordinating resolution of 
Institutional Review Board issues, facilitating the conduct of the 
study and on-going data collection, analyses, and reporting of study 
results.
    c. Participate in the methodology and protocol development, on-
going data collection and follow-up, quality control, data analysis and 
interpretation, the preparation of peer-reviewed publications, and 
presentation of findings.
    d. Work cooperatively with the other Centers, and agree to follow 
the common protocol(s) and manual(s) of operations developed in Phase I 
of the study by the Steering Committee.
    e. Maintain an effective and adequate management and staffing plan. 
Staff should have the education, background, and experience to 
successfully conduct the activities proposed in this application. As a 
part of the application, the existing staff and all proposed positions 
should to be included.

2. CDC Activities

    a. Support the recipients' activities by collaborating and 
providing scientific and public health consultation and assistance in 
the development of activities related to the cooperative agreement and 
coordination sharing.
    b. Assist in facilitating communication among recipients 
development of common multi-center protocol(s), quality control, 
interim data monitoring, data analysis, interpretation, reporting, and 
coordination.
    c. Assist in the development of a research protocol for IRB review 
by all cooperating institutions participating in the research project, 
including CDC IRB.
    d. Serve as a consultant to the Steering Committee.

E. Application Content

Competing Applications

    Use the information in the Program Requirements, Other 
Requirements, and Evaluation Criteria sections of the announcement and 
the Errata Sheet in the application to develop the application content. 
Your application will be evaluated on the criteria listed, so it is 
important to follow them in laying out your program plan.
    The outcome of this program should provide reliable estimates of 
the prevalence, incidence and secular trends of the different types of 
childhood diabetes, and should enable the development of case 
definition and characterization at diagnosis and follow-up of the 
different types of childhood diabetes. More specifically, the following 
questions should be answered:
    1. Using existing data of known prevalent cases of childhood 
diabetes, how could prevalent cases be classified, and what are the 
type-specific prevalence estimates and the characteristics (including 
medical care received) of the different types of childhood diabetes?
    2. Based on the extensive collection of new data, how could 
incident cases of childhood diabetes be classified, and what are the 
accurate and precise population-based estimates of the type-specific 
incidence and secular trends, and the characteristics (including 
medical care received) of the different types of diabetes.
    3. How could incident cases of childhood diabetes be followed in a 
uniform approach, and what are their characteristics, outcomes and 
quality of care at follow-up? How could a ``pool'' of incident cases be 
maintained for studying secular trends in incidence and factors 
associated with causation?
    Emphasis should be on rigorous scientific approaches and 
methodologies that should yield access to populations of diverse 
ethnicity, socioeconomic status and insurance coverage, produce 
reliable population-based estimates that should adequately address 
ascertainment biases, and should assure sustainability to provide data 
for secular trend assessment and follow-up for the different types of 
childhood diabetes.

[[Page 37144]]

    Each applicant must describe the proposed populations, the 
methodology and study designs that best address the objectives of this 
program, as well as the networks and partnerships that should help 
achieve these objectives. Applications should propose a uniform and 
multi-center approach, which considers the problem of racial/ethnic 
health disparities.
    Collaborative protocol(s) to study the above questions should be 
developed by a Steering Committee composed of the recipients. The 
collaborative study protocol(s) should move into the implementation 
stage with the concurrence of the Steering Committee. It is not the 
intent of this Program Announcement to solicit elaborately detailed 
research plans for the above proposed collaborative project because the 
final protocol(s) should be collaboratively developed by the 
investigators during the planning phase (Phase I).
    Eligibility characteristics must be clearly specified with 
appropriate documentation in the Application Requirements section of 
your application.
    The application narrative must include the following sections in 
the order presented below:
    a. Description and rationale of (a) the population source 
(including size, age, ethnicity, medical insurance status, socio-
economic status, geographic), and
    b. The partnership/network(s) which will provide access to 
information on the cases within this population source (not to exceed 5 
pages).
    (1) When describing the population source, indicate the degree to 
which racial and ethnic minority and socio-economically disadvantaged 
populations are included, and how the population is sufficiently 
typical of children with diabetes around the country or accurately 
represents special groups of children with the disease.
    (2) When describing the partnership/network(s), detail the various 
types of providers which are included.
    (3) Describe why and to what extent different types of childhood 
diabetes will be captured, and detail all (hospital and non hospital) 
data sources that will be used.
    (4) Discuss how the population size (denominator) will be 
ascertained for estimation of incidence and secular trends over the 5 
years of study.
    (5) Discuss how the population-based estimates will be tested.
    (6) Discuss how the networks/partnerships will be sustained over a 
long term to allow for trend estimates, follow-up, and maintenance of a 
``pool'' of incident cases. Describe potential provider or patient 
incentives that may be used to assure sustainability and follow-up.
    (7) Include a discussion of the rationale, benefits and problems 
that may be faced in relation to the selected population source and 
partnership/network(s) developed, and describe the extent to which the 
choice of the population source and the networks/partnerships is 
scientifically sound, realistic, and likely to provide reliable 
population-based estimates and secular trends for childhood diabetes.
    c. Methodology: Case ascertainment, typology characterization, and 
follow-up of (a) the prevalent cases, and (b) the incident cases (not 
to exceed 5 pages).
    (1) Describe why and how the previously collected data on prevalent 
cases of childhood diabetes will be available, and include a 
description of the case characteristics (including number, age, sex, 
ethnicity, medical insurance status or socio-economic status, 
geographic).
    (2) Describe why and how information on a large number of incident 
cases of childhood diabetes (50 a year) will be available 
for each year of the study, and will approach complete ascertainment of 
diagnosed childhood diabetes in the population source. Describe various 
strategies to:
    (3) Ascertain the prevalent and incident cases.
    (4) Collect information to type and characterize the different 
prevalent and incident types of childhood diabetes.
    (5) Follow the incident cases for characterization and maintenance 
of a ``pool'' of incident cases.
    (6) Address potential for mis-classifications at baseline for 
prevalent and incident cases, and changes at follow-up for the incident 
cases, and other biases.
    Note that characterization for (a) and (b) should include health 
care received, potential outcomes, and risk factor levels, and should 
use low-cost and realistic methods. Note that all proposed approaches 
should discuss cost implications (cost per case identified and cost per 
case maintained).
    Also, note that emphasis should be on accurate estimation of 
incidence (to approach complete ascertainment of newly diagnosed 
childhood diabetes), as opposed to estimation of prevalence, which is 
based on previously collected information. It is not anticipated in 
this announcement that screening programs will be initiated to approach 
complete ascertainment of incidence, but if such screening programs are 
independently implemented, they may constitute a valuable addition to 
the present study.
    d. Standardization across sites (not to exceed 1 page):
    (1) Discuss how methods for identification and classification of 
childhood diabetes cases could be standardized across sites and over 
the study period;
    (2) Discuss how the design and the standardization will ensure that 
maximum and wide use of the system will be made and sustained.
    e. Background and experience of the principal investigator, co-
investigators, and the applying institution, organization, or agency 
(not to exceed 3 pages).
    (1) Describe the educational and professional background of the 
principal investigator.
    (2) Document the relevant experience of the principal investigator 
and qualifications of the applying institution, organization, or agency 
for carrying out epidemiological or surveillance research in chronic 
disease (including access to computerized data systems and other 
relevant resources) and collaborative, multi-center research projects.
    (3) Describe existing partnership/network(s) with other agencies/
organizations/institutions or others (specifically, involvement in 
existing or past registries of type 1 diabetes or other similar systems 
designed for disease monitoring), and with supportive State Health 
Departments, Diabetes Control Programs, or other relevant 
organizations, for the purpose of relevant medical research.
    (4) Attach evidence of collaborations and partnerships, specifying 
the commitment of the parties involved in partnership/networking(s), 
and provide details, including the terms of access to data and to 
populations and any specified limits to collaboration.
    (5) Provide a brief description of how the project will be 
organized, and indicate the proposed staffing plan and expertise, and 
the time line.
    f. Human Subjects. Address the requirements of Title 45 CFR 46 for 
the protection of human subjects, and detail the degree to which CDC 
Policy requirements regarding the inclusion of women, ethnic, and 
racial groups in the proposed research are met. This includes:
    (1) The proposed plan for the inclusion of both sexes and racial 
and ethnic minority populations for appropriate representation.
    (2) The proposed justification when representation is limited or 
absent.
    (3) A statement as to whether the design of the study is adequate 
to measure differences when warranted.

[[Page 37145]]

    (4) A statement as to whether the plans for recruitment and 
outreach for study participants include the process of establishing 
partnerships with community(ies) and recognition of mutual benefits.
    g. Budget and budget justification (not to exceed 5 pages).
    Provide a detailed, line-item budget with justification that 
demonstrates the request is consistent with the purpose and objectives 
of this program. The budget for Phase I of the study should be clearly 
delineated. Budgets should allow for approximately three persons, 
including the principal investigator, to attend Steering Committee and 
Subcommittee meetings. The detailed budget for Phase I should be 
planned and developed to assure that the project protocol may be 
written within the first nine months utilizing Steering Committee 
meetings and teleconference calls by the Steering.

Typing and Mailing

    All pages must be clearly numbered and a complete index to the 
application and its appendixes must be included. Do not bind, staple, 
or paper clip any pages of any copy of the application, including 
appendixes. Do not include any bound documents (e.g., pamphlets or 
other publications) in the appendixes. Do not include cardboard, 
plastic, or other page separators between the sections. The entire 
application must be typewritten, single-spaced, and in unreduced type 
(12-point fonts) on 8\1/2\" x 11" white paper, with at least 1" 
margins, including headers and footers, and printed on one side only.

F. Submission and Deadline

Letter of Intent (LOI)

    Your letter of intent should include the following information: The 
name and address of the applying institution, telephone number of the 
contact person, and the program announcement number.
    The letter of intent must be submitted on or before, June 30, 
2000,to the Grants Management Specialist, as identified in the ``Where 
to Obtain Additional Information'' section of this announcement.

Application

    Submit the original and five copies of form PHS 398. Forms are 
available at the following Internet address: http://www.cdc.gov/od/pgo/forminfo.htm or in the application kit. Submit the application on or 
before July 21,2000, to the Grants Management Specialist identified in 
the section ``Where to Obtain Additional Information.''
    Deadline: Applications shall be considered as meeting the deadline 
if they are either:
    (a) Received on or before the deadline date; or
    (b) Sent on or before the deadline date and received in time for 
orderly processing. (Applicants must request a legibly dated U.S. 
Postal Service postmark or obtain a legibly dated receipt from a 
commercial carrier or U.S. Postal Service. Private metered postmarks 
shall not be acceptable as proof of timely mailing.)
    Late Applications: Applications which do not meet the criteria in 
(a) or (b) above are considered late applications, will not be 
considered, and will be returned to the applicant.

G. Evaluation Criteria (Total 100 Points)

    Each application will be evaluated individually against the 
following criteria by an independent review group appointed by CDC.
    1. Description and rationale for the population and partnership/
network(s) (25 points):
    a. The extent to which (1) the population is described, (2) the 
rationale, benefits and problems that may be faced in relation to the 
population are discussed, and (3) the approach selected is 
scientifically sound, realistic, and likely to provide reliable 
population-based estimates and characterization of the different types 
of childhood diabetes. In particular, the extent to which data sources 
other than hospitalization data will be available.
    b. The extent to which (1) the partnership/network(s) is described, 
(2) the rationale, benefits and problems that may be faced in relation 
to the partnership/network(s) are discussed, and (3) the network/
partnership(s) selected are scientifically sound, realistic, and likely 
to provide reliable population-based estimates and characterization of 
the different types of childhood diabetes. In particular, the extent to 
which different types and sources of providers are available.
    c. The degree to which (1) racial/ethnic minority and socio-
economically disadvantaged populations and both sexes are included, (2) 
the population is sufficiently typical of children with diabetes around 
the country or accurately represents special groups of children with 
the disease, and (3) different types of childhood diabetes will be 
captured.
    d. The extent to which the ascertainment of the population source 
and testing of the population-based estimates are scientifically sound, 
realistic, and likely to provide reliable and accurate population-based 
estimates and secular trends for childhood diabetes.
    e. The extent to which the population and partnership/network(s) 
will be sustained over the study duration, and will allow for secular 
trends assessment, follow-up of incident cases, and maintenance of a 
``pool'' of incident cases.
    2. Rational for case ascertainment, typology, and characterization 
of prevalent cases (15 points):
    a. The extent to which previously collected data on prevalent cases 
of childhood diabetes are described, and the size, characteristics, 
quality, and accessibility of this information.
    b. The extent to which various strategies are described, and are 
sound, realistic, and feasible for case ascertainment.
    c. The extent to which various strategies are described, and are 
sound, realistic, and feasible for collection of information to type 
and characterize the different types of childhood diabetes, and the 
extent to which characterization includes health care received, 
potential outcomes, and risk factor levels.
    d. The extent to which various strategies are described, and are 
sound, realistic, and feasible for assessment of potential 
misclassifications, and other biases.
    e. The extent to which low-cost and realistic methods are used, and 
cost implications are discussed (cost per case identified).
    3. Rationale for the methodology, case ascertainment, typology, 
characterization, and follow-up of incident cases (25 points).
    a. The extent to which information on a large number of incident 
cases of childhood diabetes (50 a year) is available and 
described, and will approach complete ascertainment of diagnosed 
childhood diabetes in the population source.
    b. The extent to which various strategies are described and are 
realistic, feasible, and sustainable over 5 years for ascertainment of 
incident cases.
    c. The extent to which (1) various strategies are described and are 
realistic, feasible, and sustainable over 5 years for collection of 
information to type and characterize the difference types of childhood 
diabetes, (2) characterization includes health care received, potential 
outcomes, and risk factor levels, and (3) potential mis-classifications 
at baseline, and changes at follow-up, and other biases are assessed.
    d. The extent to which various strategies are described and are 
realistic, feasible, and sustainable over 5 years for follow-up of 
incident cases for

[[Page 37146]]

characterization, typology and maintenance of a ``pool'' of incident 
cases.
    e. The extent to which low-cost and realistic methods are used, and 
cost implications (cost per case identified and cost per maintained) 
are discussed.
    4. Standardization across sites (15 points):
    a. The extent to which the proposed approach to childhood diabetes 
research is specific, realistic, time-phased, and suitable for 
development into a collaborative, multi-center study protocol.
    b. The extent to which the applicant presents a detailed 
operational plan for initiating and conducting the project that clearly 
and appropriately addresses all Recipient Activities.
    c. The extent to which applicant describes collaborations with 
other sites during the various phases of the project, and shows 
commitment to implement a standardized, multi-center, collaborative 
approach.
    5. Background and Experience of the Principal Investigator and of 
the Applying Institution, Organization, or Agency (20 points):
    a. The educational and professional background of the principal 
investigator, and the relevant experience of the principal investigator 
and qualifications of the applying institution, organization, or agency 
for carrying on epidemiological or surveillance research in chronic 
diseases (including access to computerized data systems and other 
relevant resources) or multi-center research projects.
    b. Existence of partnership/network(s) with other agencies/
organizations/institutions or others (specifically, involvement in 
existing or past registries of type 1 diabetes or other similar systems 
designed for disease monitoring), and with supportive State Health 
Departments, Diabetes Control Programs, or other relevant 
organizations, for the purpose of relevant medical research. Evidence 
that commitment of the parties involved in partnership/networking for 
this specific project is provided, including the terms of access to 
data and to populations, and any specified limits to collaboration for 
the purposes of this project.
    c. The extent to which a brief description is provided on how the 
project will be organized, what the time line and the proposed staffing 
plan will be, and the extent to which the applicant clearly identifies 
specific assigned responsibilities and time commitment of all key 
professional personnel.
    6. Human subjects (Not scored) Does the application adequately 
address the requirements of Title 45 CFR Part 46 for the protection of 
human subjects? The degree to which the applicant has met the CDC 
Policy requirements regarding the inclusion of women, ethnic, and 
racial groups in the proposed research. This includes: (a) the proposed 
plan for the inclusion of both sexes and racial and ethnic minority 
populations for appropriate representation, (b) the proposed 
justification when representation is limited or absent, (c) a statement 
as to whether the design of the study is adequate to measure 
differences when warranted, (d) a statement as to whether the plans for 
recruitment and outreach for study participants include the process of 
establishing partnerships with community(ies) and recognition of mutual 
benefits.
    7. Budget and Budget Justification (Not scored): The extent to 
which the budget is reasonable and consistent with the purpose and 
objectives of this program; and specification and discussion of cost 
per case identified, cost per case maintained, and cost per case type-
classified.

H. Other Requirements

Technical Reporting Requirements

    Provide CDC with an original plus two copies of the following:
    1. Progress reports (semiannual);
    2. Financial status report, no more than 90 days after the end of 
the budget period; and
    3. Final financial and performance reports, no more than 90 days 
after the end of the project period.
    Send all reports to the Grants Management Specialist identified in 
the ``Where to Obtain Additional Information'' section of this 
announcement.
    The following additional requirements are applicable to this 
program. For a complete description of each, see Attachment I in the 
application kit.

AR-1  Human Subjects Requirements
AR-2  Requirements for Inclusion of Women and Racial and Ethnic 
Minorities in Research
AR-7  Executive Order 12372 Review
AR-9  Paperwork Reduction Act Requirements
AR-10  Smoke-Free Workplace Requirements
AR-11  Healthy People 2010
AR-12  Lobbying Restrictions
AR-15  Proof of Non-Profit Status

I. Authority and Catalog of Federal Domestic Assistance Number

    This program is authorized under sections 301(a) and 317(k)(2) [42 
U.S.C. 241(a) and 247b(k)(2)] of the Public Health Service Act, as 
amended. The Catalog of Federal Domestic Assistance number is 93.988.

J. Where To Obtain Additional Information

    To receive additional written information and to request an 
application kit, call 1-888-GRANTS4 (1-888-472-6874). You will be asked 
to leave you name and address and will be instructed to identify the 
Announcement number of interest.
    If you have questions after reviewing the contents of all the 
documents, business management technical assistance may be obtained 
from: Barry L. Copeland, Grants Management Specialist, Grants 
Management Branch, Procurement and Grants Office, Announcement #00097, 
Centers for Disease Control and Prevention, Room 3000, 2920 Brandywine 
Road, Atlanta, GA 30341-4146, Telephone number (770) 488-2762, Email 
address [email protected].
    This and other CDC announcements can be found on the CDC homepage 
internet address: http://www.cdc.gov See Attachment II for background 
on the program. For program technical assistance, contact: Anne Fagot-
Campagna, Division of Diabetes Translation, Centers for Disease Control 
and Prevention, 4770 Buford HWY, NE, Mailstop K-68, Atlanta GA, 30341, 
telephone number (770) 488-1053 (or -1069), Email address [email protected].

    Dated: June 6, 2000.
Henry S. Cassel, III,
Deputy Director, Procurement and Grants Office, Center for Disease 
Control and Prevention (CDC).
[FR Doc. 00-14829 Filed 6-12-00; 8:45 am]
BILLING CODE 4163-18-P